These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11205135)

  • 1. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET.
    Brooks DJ
    J Neural Transm Suppl; 2000; (60):125-37. PubMed ID: 11205135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging end points for monitoring neuroprotection in Parkinson's disease.
    Brooks DJ
    Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.
    Thobois S; Guillouet S; Broussolle E
    Neurophysiol Clin; 2001 Oct; 31(5):321-40. PubMed ID: 11817273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
    Morrish PK
    Mov Disord; 2003 Oct; 18 Suppl 7():S63-70. PubMed ID: 14531048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection and imaging studies in Parkinson's disease.
    Pavese N; Kiferle L; Piccini P
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S33-7. PubMed ID: 20123554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging in Parkinson's disease.
    Brooks DJ
    NeuroRx; 2004 Apr; 1(2):243-54. PubMed ID: 15717025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it time to abandon functional imaging in the study of neuroprotection?
    Morrish P
    Mov Disord; 2002 Mar; 17(2):229-32. PubMed ID: 11921106
    [No Abstract]   [Full Text] [Related]  

  • 8. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Advantages and limitations in the assessment of neuroprotective treatment of Parkinson's disease by functional imaging].
    Thobois S; Broussolle E; Remy P
    Rev Neurol (Paris); 2005 Apr; 161(4):385-93. PubMed ID: 15924074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease process and drug treatments in Parkinson's disease.
    Leenders KL
    Eur Neuropsychopharmacol; 2002 Dec; 12(6):575-80. PubMed ID: 12468020
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroprotection in idiopathic Parkinson's disease.
    Reichmann H
    J Neurol; 2002 Oct; 249 Suppl 3():III/21-3. PubMed ID: 12522567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. REAL and CALM: what have we learned?
    Morrish PK
    Mov Disord; 2003 Jul; 18(7):839-40. PubMed ID: 12815670
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuroprotective Effects of Rasagiline in Parkinson's Disease: A Regional Cerebral Blood Flow Study.
    Im JJ; Jeong H; Chung YA; Park JS; Heo Y; Oh JK; Song IU
    J Neuroimaging; 2019 Nov; 29(6):707-711. PubMed ID: 31463990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Movement disorders: understanding clinical trials.
    Goetz CG
    Lancet Neurol; 2005 Jan; 4(1):5-6. PubMed ID: 15620847
    [No Abstract]   [Full Text] [Related]  

  • 15. Pathophysiology of movement disorders studied using PET.
    Leenders KL
    J Neural Transm Suppl; 1997; 50():39-46. PubMed ID: 9120423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The harsh realities facing the use of SPECT imaging in monitoring disease progression in Parkinson's disease.
    Morrish PK
    J Neurol Neurosurg Psychiatry; 2003 Oct; 74(10):1447; author reply 1447. PubMed ID: 14570850
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroprotection for Parkinson's disease.
    Koller WC
    Ann Neurol; 1998 Sep; 44(3 Suppl 1):S155-9. PubMed ID: 9749588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
    de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V
    Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
    Hälbig TD; Tse W; Olanow CW
    Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.